| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 05/10/2001 | WO2001032217A2 Pharmacological inducement of the fed mode for enhanced drug administration to the stomach |
| 05/10/2001 | WO2001032204A2 Nucleic acid vaccine compositions having a mammalian cd80/cd86 gene promoter driving antigen expression |
| 05/10/2001 | WO2001032203A1 Protease inhibitors as modulators of periodontal wound healing |
| 05/10/2001 | WO2001032201A2 A pharmaceutical composition having high cell membrane permeability |
| 05/10/2001 | WO2001032181A2 Pharmaceutical compositions containing a fluoroquinolone antibiotic drug and xanthan gum |
| 05/10/2001 | WO2001032180A2 Composition for treatment of constipation and irritable bowel syndrome |
| 05/10/2001 | WO2001032165A1 Method for administering a phosphodiesterase 4 inhibitor |
| 05/10/2001 | WO2001032152A1 Edible mcc/pga coating composition |
| 05/10/2001 | WO2001032150A1 Edible coating composition |
| 05/10/2001 | WO2001032149A1 Osmotic controlled release drug delivery device |
| 05/10/2001 | WO2001032146A2 Amphiphilic polymeric vesicles |
| 05/10/2001 | WO2001032144A1 Dry powder compositions having improved dispersivity |
| 05/10/2001 | WO2001032139A2 Method for the formulation of substances having a low water-solubility and lipophilicity and formulation thus obtained |
| 05/10/2001 | WO2001032130A2 Phenyl amine carboxylic acid compounds and compositions for delivering active agents |
| 05/10/2001 | WO2001032125A2 Apparatus and process for preparing crystalline particles |
| 05/10/2001 | WO2001032115A1 Transdermal administration of huperzine |
| 05/10/2001 | WO2001032036A1 Cholesterol reducing stanol compositions, preparation and method of use |
| 05/10/2001 | WO2001032031A2 Cholesterol reducing sterol compositions, preparation and method of use |
| 05/10/2001 | WO2001019378A3 Solid lipid formulations comprising an inhibitor of lipases and a fatty acid ester of polyols |
| 05/10/2001 | WO2001016306A3 Chimeric antisense oligonucleotides and cell transfecting formulations thereof |
| 05/10/2001 | WO2001012175A8 Uses compositions for treating or preventing sleep disturbances using very low doses of cyclobenzaprine |
| 05/10/2001 | WO2001008505A3 Methods for suppressing appetite and enhancing exercise and recovery |
| 05/10/2001 | WO2001007469A3 Polypeptide dendrimers as unimolecular carriers of diagnostic imaging contrast agents, bioactive substances and drugs |
| 05/10/2001 | WO2001001922A3 Use of substance p antagonists for the treatment of adenocarcinoma |
| 05/10/2001 | WO2000072690A3 IMMOBILIZED LACTOFERRIN (Im-LF) ANTIMICROBIAL AGENTS AND USES THEREOF |
| 05/10/2001 | WO2000067800A3 Medicament vehicle for the controlled administration of an active agent, produced from lipid matrix-medicament conjugates |
| 05/10/2001 | WO2000061170A3 Novel medical use of alpha-1-acidic glycoprotein (aag or orosomucoid) |
| 05/10/2001 | WO2000033888A9 Prodrug compounds and process for preparation thereof |
| 05/10/2001 | WO2000016745A3 Micronised pharmaceutical compositions |
| 05/10/2001 | CA2390077A1 Composite nanospheres and their conjugates with biomolecules |
| 05/10/2001 | CA2390025A1 Phenyl amine carboxylic acid compounds and compositions for delivering active agents |
| 05/10/2001 | CA2389908A1 Novel apparatus and process for preparing crystalline particles |
| 05/10/2001 | CA2389865A1 Transdermal administration of huperzine |
| 05/10/2001 | CA2389778A1 Oligobenzimidazole derivatives and their use as dna transfection agents |
| 05/10/2001 | CA2389693A1 Dna-vaccines based on constructs derived from the genomes of human and animal pathogens |
| 05/10/2001 | CA2389690A1 Selective toxin expression in angiogenic endothelial cells |
| 05/10/2001 | CA2389680A1 Nucleic acid vaccine compositions having a mammalian cd80/cd86 gene promoter driving antigen expression |
| 05/10/2001 | CA2389663A1 Protease inhibitors as modulators of periodontal wound healing |
| 05/10/2001 | CA2389605A1 Cholesterol reducing stanol compositions, preparation and method of use |
| 05/10/2001 | CA2389304A1 Compositions and methods for controlled-release delivery and increased potency of pharmaceuticals via hydrophobic ion-pairing |
| 05/10/2001 | CA2389293A1 Method for administering a phosphodiesterase 4 inhibitor |
| 05/10/2001 | CA2389236A1 Pharmacological inducement of the fed mode for enhanced drug administration to the stomach |
| 05/10/2001 | CA2389147A1 Method for the formulation of substances having a low water-solubility and lipophilicity and formulation thus obtained |
| 05/10/2001 | CA2388339A1 Cholesterol reducing sterol compositions, preparation and method of use |
| 05/10/2001 | CA2388187A1 Treatment of c. difficile toxin b associated conditions |
| 05/10/2001 | CA2388159A1 Osmotic controlled release drug delivery device |
| 05/10/2001 | CA2388028A1 Method of inactivating pathogens |
| 05/10/2001 | CA2386822A1 Pharmaceutical compositions containing a fluoroquinolone antibiotic drug and xanthan gum |
| 05/10/2001 | CA2358921A1 Oxetanone derivatives |
| 05/09/2001 | EP1097968A1 Mixtures of silicone elastomers |
| 05/09/2001 | EP1097942A2 Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes |
| 05/09/2001 | EP1097922A1 5-thia-omega-substituted phenyl-prostaglandin e derivatives, process for producing the same and drugs containing the same as the active ingredient |
| 05/09/2001 | EP1097722A1 Excipient |
| 05/09/2001 | EP1097721A2 Oil-based adjuvant vaccine |
| 05/09/2001 | EP1097715A1 Preparations for immunotherapy for cancer having bacterial somatic constituent as the active ingredient |
| 05/09/2001 | EP1097712A1 Steroid-containing cataplasms and process for producing the same |
| 05/09/2001 | EP1097696A1 Composition containing waxes and an hydrophilic active unstable in an oxidizing medium and cosmetic use thereof |
| 05/09/2001 | EP1097198A2 Soluble derivatives of anti-angiogenic peptides |
| 05/09/2001 | EP1097168A2 Compounds and methods for modulating cadherin-mediated functions |
| 05/09/2001 | EP1096994A1 Liquid thickener for surfactant systems |
| 05/09/2001 | EP1096962A1 Method of obscuring immune recognition |
| 05/09/2001 | EP1096957A1 Methods and reagents for intramuscular delivery of nucleic acids |
| 05/09/2001 | EP1096955A2 Cancer treatment methods using antibodies to aminophospholipids |
| 05/09/2001 | EP1096954A2 Adjuvant and vaccine compositions containing monophosphoryl lipid a |
| 05/09/2001 | EP1096949A2 Treatment of celiac disease with interleukin-15 antagonists |
| 05/09/2001 | EP1096937A2 Sustained release ranolazine formulations |
| 05/09/2001 | EP1096922A1 Improved stable topical ascorbic acid compositions |
| 05/09/2001 | EP1096921A1 Liposomal encapsulated nucleic acid-complexes |
| 05/09/2001 | CN1294582A Novel nucleic acid trangsfer agents, compsns, contg. same and uses |
| 05/09/2001 | CN1294520A Polynucleotide compsn. method of prepn. and use thereof |
| 05/09/2001 | CN1294519A Pharmaceutical Compsns. contg. compounds with activity for enhancement of absorption of active ingredients |
| 05/09/2001 | CN1294518A Remidies for hepatitis |
| 05/09/2001 | CN1294511A Medicinal compsns. |
| 05/09/2001 | CN1294509A Enteric coated pharmaceutical compsn. and method of mfg. |
| 05/09/2001 | CN1294017A Ceramide lipsome emulsion containing VA and its preparing process and usage |
| 05/09/2001 | CN1065433C Oily prepn. and method of prodn. thereof |
| 05/09/2001 | CN1065428C Matrix type patch preparations |
| 05/09/2001 | CN1065415C Application of protein and lipid composite for modifying taste |
| 05/08/2001 | US6229002 Complex of nucleic acid which binds to platelet derived growth factor and nonimmunogenic, high molecular weight compound; for targeted diagnostic and therapy; anticarcinogenic agents; cardiovascular disorders; kidney disease |
| 05/08/2001 | US6228969 Biodegradable polyester urethanes, method for the production and use thereof |
| 05/08/2001 | US6228836 Administering cyclic nonapeptide n-terminated with b,b-(3-thiapentamethylene)-b-mercaptopropionic acid |
| 05/08/2001 | US6228423 Biodegradable targetable microparticle delivery system |
| 05/08/2001 | US6228401 Processes for preparing flutamide compounds and compounds prepared by such processes |
| 05/08/2001 | US6228400 Orally administered pharmaceutical formulations of benzimidazole derivatives and the method of preparing the same |
| 05/08/2001 | US6228399 Cyclosporin, a phospholipid and at least one surface modifier, |
| 05/08/2001 | US6228398 Dosage form for increasing patient compliance by reducing dosage frequency; attention deficit disorder, methylphenidate or salts |
| 05/08/2001 | US6228397 Pharmaceutical composition having two coating layers |
| 05/08/2001 | US6228395 Sustained-release microgranules containing Diltiazem as the active principle |
| 05/08/2001 | US6228394 Supercritical fluid extraction of mould lubricant from hard shell capsules |
| 05/08/2001 | US6228392 Osmotic delivery composition, solution, and method |
| 05/08/2001 | US6228383 Active substance and protective substance |
| 05/08/2001 | US6228376 Adhesive cooling composition and process for its preparation |
| 05/08/2001 | US6228362 Boron neutron capture therapy using pre-targeting methods |
| 05/08/2001 | US6228249 Electrolytic purification of calcium carbonate |
| 05/08/2001 | US6227195 Coarse spray delivery of functional biologic material |
| 05/08/2001 | CA2122638C Formation of stable liposomes from lipid extracts of archaeobacteria (archaea) |
| 05/03/2001 | WO2001031020A1 Disulfide conjugated cell toxins and methods of making and using them |
| 05/03/2001 | WO2001031006A2 Serum amyloid a isoform from colostrum |
| 05/03/2001 | WO2001030997A2 Microbe, microbial exopolysaccharide, and uses thereof |
| 05/03/2001 | WO2001030996A2 Microbial exopolysaccharide and uses thereof |